ESMO 2014: The ‘National Lung Matrix’ trial – a new strategy for cancer drug research

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ‘National Lung Matrix’ trial, which is a collaboration between Cancer Research UK, AstraZeneca and Pfizer. This approach aims to improve the interaction between academia and industry, thereby facilitating the development of molecularly defined treatments in lung cancer.

Year of Production:
Running Time:
Color/Sound:

2015
01:58
Color/Sound

Comments are closed.